Decreased CBF precedes the detectable changes of classical Aβ and tau biomarkers, as well as brain atrophy, suggesting that reduced CBF could be a valuable biomarker in preclinical AD [138, 179]. The gene discussed is MAPT; the disease is Alzheimer disease.